← Back to Clinical Trials
Recruiting NCT06651333

NCT06651333 fMRI and Opioid Abstinence

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06651333
Status Recruiting
Phase
Sponsor Yale University
Condition Drug Use Disorder
Study Type OBSERVATIONAL
Enrollment 240 participants
Start Date 2024-12-12
Primary Completion 2029-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 50 Years
Study Type OBSERVATIONAL
Interventions
fMRI

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 240 participants in total. It began in 2024-12-12 with a primary completion date of 2029-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project examines functional connectivity patterns associated with subsequent relapse to illicit opioids during treatment for OUD.

Eligibility Criteria

Inclusion Criteria: * recent initiation of methadone or buprenorphine at a clinic or program within the past year (i.e., period of time during which treatment drop-out and risk for relapse is highest); * eligibility for MRI scanning; * ability to commit to study visits. Exclusion Criteria: * current acute psychosis, mania, or suicidal ideation with intent, as assessed during screening with the SCID-5; * current intoxication or acute withdrawal at time of study visit sufficient to prevent participation based on: behavioral observation, breathalyzer, and SOWS assessment; * severe cognitive impairment as determined via trained clinical research staff through consent process and during consent quiz or as indicated by a PROMIS Cognitive Function tscore \<30 (i.e., severe impairment) * past or present history of intellectual disability, developmental disorder, or neurological disease; * head trauma with loss of consciousness \>30 min; * organ dysfunction or any unstable or untreated medical conditions that may interfere with study participation.

Contact & Investigator

Central Contact

Monica Holler, BS

✉ monica.holler@yale.edu

📞 203 737 3531

Principal Investigator

Sarah Yip, PhD, MSc

PRINCIPAL INVESTIGATOR

Yale University

Frequently Asked Questions

Who can join the NCT06651333 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Drug Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06651333 currently recruiting?

Yes, NCT06651333 is actively recruiting participants. Contact the research team at monica.holler@yale.edu for enrollment information.

Where is the NCT06651333 trial being conducted?

This trial is being conducted at New Haven, United States.

Who is sponsoring the NCT06651333 clinical trial?

NCT06651333 is sponsored by Yale University. The principal investigator is Sarah Yip, PhD, MSc at Yale University. The trial plans to enroll 240 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology